8-KEarnings & ResultsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Results (Oct 16, 2024)

Filed October 16, 2024For Securities:ABT

Summary

Abbott Laboratories (ABT) has filed an 8-K report on October 16, 2024, to announce its third-quarter 2024 financial results. The report primarily references a press release issued on October 16, 2024, which details these results and includes the use of various non-GAAP financial measures. Investors should note that these non-GAAP measures are presented to offer a clearer view of ongoing business performance by excluding items such as acquisition-related expenses, restructuring costs, and fair value adjustments. While Abbott's management believes these non-GAAP metrics provide valuable insights, they are intended to supplement, not replace, GAAP-based financial measures. The filing highlights the company's emphasis on providing transparency into its operational performance beyond standard accounting practices, allowing for a better evaluation of core business trends. Investors are encouraged to review the provided press release for the specific financial figures and further details on the non-GAAP adjustments.

Key Highlights

  • 1Abbott Laboratories announced its third-quarter 2024 financial results on October 16, 2024, via an 8-K filing.
  • 2The results are detailed in a press release furnished as Exhibit 99.1.
  • 3The company utilized non-GAAP financial measures in its earnings announcement.
  • 4Non-GAAP measures exclude items such as acquisition costs, restructuring, and fair value adjustments.
  • 5Abbott's management believes these non-GAAP measures offer better insight into ongoing business performance.
  • 6Investors are advised to consider non-GAAP measures alongside GAAP financial results.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce Abbott Laboratories' financial results for the third quarter of 2024.

The detailed financial results are provided in the press release dated October 16, 2024, which is attached as Exhibit 99.1 to this 8-K filing.

Non-GAAP financial measures are financial metrics that exclude certain items from GAAP (Generally Accepted Accounting Principles) figures. Abbott uses them to provide investors with a clearer view of ongoing business performance by excluding items such as acquisition expenses, restructuring costs, and fair value adjustments, which management believes are unusual or unpredictable.

No, Abbott's management advises investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP. This means you should look at both GAAP and non-GAAP figures for a complete understanding.